Latest On Intellia Therapeutics, Inc (NTLA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-04 14:57 EST | News | Intellia Therapeutics GAAP EPS of -$1.17 beats by $0.21, revenue of $12.6M beats by $0.84M | N/A |  |
| 2023-05-04 14:57 EST | News | Intellia Therapeutics, Inc. 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-05-04 14:57 EST | News | Intellia Therapeutics, Inc. (NTLA) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-04 14:57 EST | News | Intellia jumps 13% after Q1 updates | N/A | |
| 2023-05-04 02:28 EST | News | Intellia Therapeutics Q1 2023 Earnings Preview | N/A | |
| 2023-04-21 23:02 EST | News | Intellia Therapeutics: Signs Of Possible Life | N/A | |
| 2023-04-14 00:52 EST | News | Intellia up 12% as Canaccord starts with Buy citing gene editing approach | N/A | |
| 2023-04-14 00:52 EST | News | Gene editing stocks rally as Wall Street turns bullish | N/A | |
| 2023-03-21 23:26 EST | News | Intellia wins key FDA designation for CRISPR candidate | N/A | |
| 2023-03-14 23:49 EST | News | Intellia gains as BMO upgrades citing recent weakness | N/A | |
| 2023-03-07 22:33 EST | News | Intellia Therapeutics: Progressing Pipeline Signals Positive Outlook For Investors | N/A | |
| 2023-03-02 19:53 EST | News | Intellia stock rises on FDA nod to start trial of CRISPR gene editing therapy | N/A | |
| 2023-02-23 17:51 EST | News | Intellia Therapeutics GAAP EPS of -$1.40 misses by $0.04, revenue of $13.6M beats by $2.89M | N/A | |
| 2023-02-23 17:51 EST | News | Intellia, Novartis end gene editing partnership for sickle cell disease | N/A | |
| 2023-02-23 17:51 EST | News | Intellia Therapeutics, Inc. (NTLA) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-22 15:55 EST | News | Intellia Therapeutics Q4 2022 Earnings Preview | N/A | |
| 2023-02-01 19:35 EST | News | Editas, Beam win bullish views as Cantor launches gene editing coverage | N/A | |
| 2023-01-24 17:59 EST | News | Intellia Therapeutics upgraded at Citi after recent selloff | N/A | |
| 2023-01-11 12:52 EST | News | Intellia awarded innovation passport in UK for genetic disorder treatment | N/A | |
| 2022-12-20 16:01 EST | News | Intellia: Most Advanced In A Tough Field | N/A | |
| 2022-12-20 16:01 EST | News | Intellia: In-Vivo Gene Editing Platform Continues To Deliver | N/A | |
| 2022-12-01 15:07 EST | News | Intellia therapeutics dips on pricing of public offering of common stock | N/A | |
| 2022-11-03 13:07 EST | News | Intellia Therapeutics GAAP EPS of -$1.49 misses by $0.21, revenue of $13.27M beats by $2.43M | N/A | |
| 2022-11-03 13:06 EST | News | Intellia Therapeutics, Inc. (NTLA) Q3 2022 Results - Earnings Call Transcript | N/A | |
| 2022-10-06 00:41 EST | News | Intellia Therapeutics: Top Speculative Trade In The Biotech Space | N/A | |
| 2022-09-16 13:20 EST | News | Intellia gains after positing early data for gene-edited hereditary angioedema candidate | N/A | |
| 2022-09-16 13:20 EST | News | Intellia, Regeneron post early data to highlight gene editing in ATTR amyloidosis cardiomyopathy | N/A | |
| 2022-09-16 13:19 EST | News | Intellia falls as analysts react to CRISPR readouts | N/A | |
| 2022-09-02 02:53 EST | News | Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling | N/A | |
| 2022-08-24 07:41 EST | News | Can Intellia One-Up Alnylam In Transthyretin Amyloidosis? | N/A | |
| 2022-08-04 14:36 EST | News | Intellia Therapeutics GAAP EPS of -$1.33 misses by $0.02, revenue of $14.03M beats by $4.53M | N/A | |
| 2022-08-04 14:36 EST | News | Intellia Therapeutics down 12% following bottom line Q2 earnings miss | N/A | |
| 2022-08-04 14:35 EST | News | Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-04 00:04 EST | News | Intellia Therapeutics Q2 2022 Earnings Preview | N/A | |
| 2022-08-03 08:59 EST | News | Alnylam drives Intellia, Ionis higher with amyloidosis data; BridgeBio slips | N/A | |
| 2022-07-30 06:35 EST | News | Intellia Therapeutics Is Pushing CRISPR-Based Therapy Forward, Slowly But Surely | N/A | |
| 2022-07-29 02:39 EST | News | Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish | N/A | |
| 2022-07-11 23:16 EST | News | Cathie Wood’s ARKK seeks first positive trading month after eight straight months of declines | N/A | |
| 2022-06-24 11:06 EST | News | Intellia, Regeneron post 12-month data for gene editing therapy in ATTR amyloidosis | N/A | |
| 2022-06-16 23:02 EST | News | Intellia Therapeutics initiated at buy at BofA on lead programs, gene editing technology | N/A | |
| 2022-05-12 21:46 EST | News | Intellia Therapeutics: Several Catalysts Expected For H2 2022 | N/A | |
| 2022-05-09 14:16 EST | News | Intellia Therapeutics stocks falls for third straight session after Q1 earnings miss | N/A | |
| 2022-05-06 05:46 EST | News | Intellia Therapeutics GAAP EPS of -$1.96 misses by $0.86, revenue of $11.25M beats by $2.68M | N/A | |
| 2022-05-06 05:46 EST | News | Intellia Therapuetics drops 5% following bottom line earnings miss, balloning R&D costs | N/A | |
| 2022-05-06 05:46 EST | News | Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-06 05:46 EST | News | Intellia Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-05-05 06:56 EST | News | Intellia Therapeutics Q1 2022 Earnings Preview | N/A | |
| 2022-04-28 16:59 EST | News | Intellia wins Outperform rating at Credit Suisse on ATTR potential | N/A | |
| 2022-03-10 03:10 EST | News | Intellia Therapeutics receives Orphan Drug Designation for CRISPR leukemia treatment | N/A | |
| 2022-03-10 03:10 EST | News | Intellia: One Patent Ruling Turns The Industry Upside Down | N/A | |
About Intellia Therapeutics, Inc (NTLA):
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
General
- Name Intellia Therapeutics, Inc
- Symbol NTLA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 312
- Fiscal Year EndDecember
- IPO Date2016-05-06
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.intelliatx.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 63.25
- Price/Book (Most Recent Quarter) 8.42
- Enterprise Value Revenue 66.89
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.83
- Next Year EPS Estimate -$3.20
- Next Quarter EPS Estimate -$0.73
- Profit Margin -231%
- Operating Margin -236%
- Return on Assets -17%
- Return on Equity -34%
- Revenue 57.99 million
- Earnings Per Share -$2.00
- Revenue Per Share $1.04
- Gross Profit -92414000
- Quarterly Earnings Growth -39.7%
View More
Highlights
- Market Capitalization 4.32 billion
- EBITDA -91114000
- PE Ratio -4.73
- Analyst Target Price $78.46
- Book Value Per Share $7.96
View More
Share Statistics
- Shares Outstanding 67.73 million
- Shares Float 64.39 million
- % Held by Insiders 1358%
- % Held by Institutions 85.75%
- Shares Short 8.09 million
- Shares Short Prior Month 8.57 million
- Short Ratio 5.09
- Short % of Float 16%
- Short % of Shares Outstanding 12%
View More
Technicals
- Beta 2.04
- 52 Week High $92
- 52 Week Low $11.02
- 50 Day Moving Average 64.28
- 200 Day Moving Average 45.31
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Intellia Therapeutics, Inc (NTLA) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Intellia Therapeutics, Inc (NTLA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-25 | $6.6 million | -$0.69 | -$0.61 | -12.75% |
| 2020-09-30 | 2020-11-05 | $N/A | -$0.47 | -$0.57 | 17.11% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.61 | -$0.67 | 9.46% |
| 2020-03-31 | 2020-05-07 | $N/A | -$0.63 | -$0.47 | -33.11% |
| 2019-12-31 | 2020-02-27 | $10.94 million | -$0.57 | -$0.56 | -2.24% |
| 2019-09-30 | 2019-10-31 | $10.62 million | -$0.49 | -$0.61 | 19.65% |
| 2019-06-30 | 2019-08-01 | $11.12 million | -$0.56 | -$0.59 | 5.02% |
| 2019-03-31 | 2019-05-02 | $10.43 million | -$0.49 | -$0.57 | 13.85% |
| 2018-12-31 | 2019-02-27 | $7.88 million | -$0.43 | -$0.54 | 20.8% |
| 2018-09-30 | 2018-10-31 | $7.41 million | -$0.53 | -$0.49 | -8.54% |
| 2018-06-30 | 2018-08-01 | $7.68 million | -$0.52 | -$0.56 | 7.47% |
| 2018-03-31 | 2018-05-01 | $7.47 million | -$0.51 | -$0.56 | 8.6% |
| 2017-12-31 | 2018-03-14 | $6.67 million | -$0.61 | -$0.45 | -36.77% |
| 2017-09-30 | 2017-10-31 | $7.32 million | -$0.44 | -$0.50 | 11.11% |
| 2017-06-30 | 2017-08-01 | $5.92 million | -$0.45 | -$0.42 | -7.99% |
| 2017-03-31 | 2017-05-02 | $6.22 million | -$0.36 | -$0.35 | -2.86% |
| 2016-12-31 | 2017-03-14 | $5.63 million | -$0.31 | -$0.21 | -46.92% |
| 2016-09-30 | 2016-11-01 | $4.87 million | -$0.22 | -$0.21 | -6.28% |
| 2016-06-30 | 2016-08-04 | $4.21 million | -$0.19 | -$0.02 | -850% |
| 2016-03-31 | 2016-06-03 | $1.78 million | -$0.19 | -$0.19 | 3.88% |
Intellia Therapeutics, Inc (NTLA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Intellia Therapeutics, Inc (NTLA) Chart:
Intellia Therapeutics, Inc (NTLA) News:
Below you will find a list of latest news for Intellia Therapeutics, Inc (NTLA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Intellia Therapeutics, Inc (NTLA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 12.5 | 0 | CALL | 0 | 0 | 308.88 | TRUE | 0 | 0 |
| 2024-05-17 | 15 | 10.4 | CALL | 0 | 1 | 266.34 | TRUE | 0 | 0 |
| 2024-05-17 | 17.5 | 7 | CALL | 1 | 7 | 195.48 | TRUE | 7 | 0 |
| 2024-05-17 | 20 | 3.84 | CALL | 3 | 66 | 77.87 | TRUE | 0.39 | 0.11 |
| 2024-05-17 | 22.5 | 2.48 | CALL | 5 | 1818 | 68.85 | TRUE | 0.69 | 0.39 |
| 2024-05-17 | 25 | 0.9 | CALL | 448 | 1474 | 88.31 | FALSE | 0.15 | 0.2 |
| 2024-05-17 | 30 | 0.15 | CALL | 119 | 835 | 88 | FALSE | -0.05 | -0.25 |
| 2024-05-17 | 35 | 0.17 | CALL | 0 | 332 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 40 | 0.1 | CALL | 0 | 39 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 12.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 15 | 0.05 | PUT | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 17.5 | 0.15 | PUT | 0 | 82 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 20 | 0.15 | PUT | 1 | 412 | 71.34 | FALSE | -0.15 | -0.5 |
| 2024-05-17 | 22.5 | 0.95 | PUT | 49 | 1912 | 83.64 | FALSE | -0.33 | -0.26 |
| 2024-05-17 | 25 | 2.3 | PUT | 57 | 131 | 83.5 | TRUE | -0.2 | -0.08 |
| 2024-05-17 | 30 | 8.2 | PUT | 0 | 0 | 131.87 | TRUE | 0 | 0 |
| 2024-05-17 | 35 | 12.6 | PUT | 0 | 5 | 175.86 | TRUE | 0 | 0 |
| 2024-05-17 | 40 | 15.86 | PUT | 1 | 1 | 266.79 | TRUE | 15.86 | 0 |
| 2024-06-21 | 12.5 | 0 | CALL | 0 | 0 | 148.36 | TRUE | 0 | 0 |
| 2024-06-21 | 15 | 0 | CALL | 0 | 0 | 140.94 | TRUE | 0 | 0 |
| 2024-06-21 | 17.5 | 0 | CALL | 0 | 0 | 117.28 | TRUE | 0 | 0 |
| 2024-06-21 | 20 | 5 | CALL | 2 | 66 | 87.4 | TRUE | 5 | 0 |
| 2024-06-21 | 22.5 | 2.78 | CALL | 0 | 1124 | 61.28 | TRUE | 0 | 0 |
| 2024-06-21 | 25 | 2.06 | CALL | 14 | 481 | 75.19 | FALSE | 0.23 | 0.13 |
| 2024-06-21 | 30 | 0.91 | CALL | 34 | 119 | 73.83 | FALSE | 0.26 | 0.4 |
| 2024-06-21 | 12.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 15 | 0.25 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 17.5 | 0.4 | PUT | 20 | 1018 | 77.64 | FALSE | 0.4 | 0 |
| 2024-06-21 | 20 | 0.75 | PUT | 5 | 33 | 76.48 | FALSE | 0.75 | 0 |
| 2024-06-21 | 22.5 | 1.85 | PUT | 2 | 4 | 73.04 | FALSE | 1.85 | 0 |
| 2024-06-21 | 25 | 3.1 | PUT | 112 | 9 | 69.37 | TRUE | 3.1 | 0 |
| 2024-06-21 | 30 | 0 | PUT | 0 | 0 | 80.15 | TRUE | 0 | 0 |
| 2024-07-19 | 12.5 | 0 | CALL | 0 | 0 | 150.87 | TRUE | 0 | 0 |
| 2024-07-19 | 15 | 6.1 | CALL | 0 | 10 | 118.89 | TRUE | 0 | 0 |
| 2024-07-19 | 17.5 | 5.8 | CALL | 0 | 20 | 91.34 | TRUE | 0 | 0 |
| 2024-07-19 | 20 | 6.2 | CALL | 5 | 289 | 81.11 | TRUE | 1.2 | 0.24 |
| 2024-07-19 | 22.5 | 3.96 | CALL | 10 | 82 | 78 | TRUE | 3.96 | 0 |
| 2024-07-19 | 25 | 2.8 | CALL | 14 | 168 | 76.07 | FALSE | 0.3 | 0.12 |
| 2024-07-19 | 30 | 1.55 | CALL | 16 | 1574 | 80.07 | FALSE | 0.35 | 0.29 |
| 2024-07-19 | 35 | 0.65 | CALL | 54 | 431 | 75.32 | FALSE | 0.15 | 0.3 |
| 2024-07-19 | 40 | 0.35 | CALL | 1 | 285 | 77.86 | FALSE | 0.35 | 0 |
| 2024-07-19 | 45 | 0.12 | CALL | 0 | 1293 | 116.2 | FALSE | 0 | 0 |
| 2024-07-19 | 50 | 0.25 | CALL | 0 | 141 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 12.5 | 0.5 | PUT | 0 | 13 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 15 | 0.55 | PUT | 0 | 34 | 134.37 | FALSE | 0 | 0 |
| 2024-07-19 | 17.5 | 0.83 | PUT | 0 | 56 | 82.66 | FALSE | 0 | 0 |
| 2024-07-19 | 20 | 1.63 | PUT | 0 | 2681 | 76.56 | FALSE | 0 | 0 |
| 2024-07-19 | 22.5 | 2.5 | PUT | 0 | 1017 | 76.86 | FALSE | 0 | 0 |
| 2024-07-19 | 25 | 3.9 | PUT | 0 | 335 | 78.53 | TRUE | 0 | 0 |
| 2024-07-19 | 30 | 10.3 | PUT | 0 | 491 | 79.43 | TRUE | 0 | 0 |
| 2024-07-19 | 35 | 13.32 | PUT | 0 | 78 | 79.58 | TRUE | 0 | 0 |
| 2024-07-19 | 40 | 13.74 | PUT | 0 | 0 | 80.04 | TRUE | 0 | 0 |
| 2024-07-19 | 45 | 23.2 | PUT | 0 | 0 | 85.05 | TRUE | 0 | 0 |
| 2024-07-19 | 50 | 29.3 | PUT | 0 | 0 | 101.26 | TRUE | 0 | 0 |
| 2024-09-20 | 12.5 | 12 | CALL | 0 | 1 | 118.07 | TRUE | 0 | 0 |
| 2024-09-20 | 15 | 10.48 | CALL | 1 | 4 | 104.58 | TRUE | 10.48 | 0 |
| 2024-09-20 | 17.5 | 5.1 | CALL | 0 | 3 | 97.86 | TRUE | 0 | 0 |
| 2024-09-20 | 20 | 5.4 | CALL | 0 | 46 | 77.8 | TRUE | 0 | 0 |
| 2024-09-20 | 22.5 | 4.59 | CALL | 0 | 60 | 75.89 | TRUE | 0 | 0 |
| 2024-09-20 | 25 | 4.5 | CALL | 1 | 383 | 77.25 | FALSE | 0.75 | 0.2 |
| 2024-09-20 | 30 | 2.4 | CALL | 7 | 1210 | 73.61 | FALSE | 0.2 | 0.09 |
| 2024-09-20 | 35 | 1.45 | CALL | 0 | 178 | 66.24 | FALSE | 0 | 0 |
| 2024-09-20 | 40 | 1.44 | CALL | 138 | 840 | 77.25 | FALSE | 1.44 | 0 |
| 2024-09-20 | 45 | 0.95 | CALL | 5 | 283 | 85.13 | FALSE | 0.95 | 0 |
| 2024-09-20 | 50 | 0.5 | CALL | 0 | 7 | 84.17 | FALSE | 0 | 0 |
| 2024-09-20 | 12.5 | 0.4 | PUT | 0 | 33 | 73.34 | FALSE | 0 | 0 |
| 2024-09-20 | 15 | 1.05 | PUT | 0 | 133 | 86.28 | FALSE | 0 | 0 |
| 2024-09-20 | 17.5 | 1.9 | PUT | 0 | 57 | 82.26 | FALSE | 0 | 0 |
| 2024-09-20 | 20 | 2.15 | PUT | 0 | 457 | 77.55 | FALSE | 0 | 0 |
| 2024-09-20 | 22.5 | 3.6 | PUT | 9 | 101 | 77.28 | FALSE | 3.6 | 0 |
| 2024-09-20 | 25 | 5.8 | PUT | 0 | 801 | 75.63 | TRUE | 0 | 0 |
| 2024-09-20 | 30 | 8.93 | PUT | 0 | 557 | 74.53 | TRUE | 0 | 0 |
| 2024-09-20 | 35 | 13 | PUT | 0 | 36 | 77.75 | TRUE | 0 | 0 |
| 2024-09-20 | 40 | 19.8 | PUT | 0 | 19 | 93.25 | TRUE | 0 | 0 |
| 2024-09-20 | 45 | 18 | PUT | 0 | 0 | 84.57 | TRUE | 0 | 0 |
| 2024-09-20 | 50 | 0 | PUT | 0 | 0 | 81.64 | TRUE | 0 | 0 |
| 2024-10-18 | 12.5 | 10.14 | CALL | 0 | 1 | 109.95 | TRUE | 0 | 0 |
| 2024-10-18 | 15 | 12.35 | CALL | 0 | 43 | 78.85 | TRUE | 0 | 0 |
| 2024-10-18 | 17.5 | 6.9 | CALL | 0 | 68 | 86.09 | TRUE | 0 | 0 |
| 2024-10-18 | 20 | 5.8 | CALL | 0 | 11 | 83.48 | TRUE | 0 | 0 |
| 2024-10-18 | 22.5 | 4.79 | CALL | 0 | 9 | 82.96 | TRUE | 0 | 0 |
| 2024-10-18 | 25 | 3.3 | CALL | 0 | 62 | 81.86 | FALSE | 0 | 0 |
| 2024-10-18 | 30 | 3.04 | CALL | 25 | 31 | 76.94 | FALSE | 3.04 | 0 |
| 2024-10-18 | 35 | 1.85 | CALL | 10 | 14 | 73.64 | FALSE | 1.85 | 0 |
| 2024-10-18 | 40 | 1.05 | CALL | 0 | 52 | 79.44 | FALSE | 0 | 0 |
| 2024-10-18 | 45 | 3.46 | CALL | 0 | 1 | 80.84 | FALSE | 0 | 0 |
| 2024-10-18 | 50 | 0 | CALL | 0 | 0 | 87.23 | FALSE | 0 | 0 |
| 2024-10-18 | 12.5 | 0.6 | PUT | 0 | 16 | 82.96 | FALSE | 0 | 0 |
| 2024-10-18 | 15 | 1.07 | PUT | 0 | 6 | 104.47 | FALSE | 0 | 0 |
| 2024-10-18 | 17.5 | 1.4 | PUT | 0 | 10 | 84.67 | FALSE | 0 | 0 |
| 2024-10-18 | 20 | 2.95 | PUT | 0 | 4 | 85.11 | FALSE | 0 | 0 |
| 2024-10-18 | 22.5 | 3.8 | PUT | 2 | 69 | 74.57 | FALSE | 3.8 | 0 |
| 2024-10-18 | 25 | 6.1 | PUT | 0 | 222 | 76.19 | TRUE | 0 | 0 |
| 2024-10-18 | 30 | 9.1 | PUT | 0 | 19 | 75.58 | TRUE | 0 | 0 |
| 2024-10-18 | 35 | 0 | PUT | 0 | 0 | 74.16 | TRUE | 0 | 0 |
| 2024-10-18 | 40 | 15.5 | PUT | 0 | 4 | 77.26 | TRUE | 0 | 0 |
| 2024-10-18 | 45 | 0 | PUT | 0 | 0 | 80.54 | TRUE | 0 | 0 |
| 2024-10-18 | 50 | 0 | PUT | 0 | 0 | 83.3 | TRUE | 0 | 0 |
| 2025-01-17 | 12.5 | 13.5 | CALL | 60 | 406 | 108.32 | TRUE | 1.45 | 0.12 |
| 2025-01-17 | 15 | 11.9 | CALL | 4 | 59 | 81.26 | TRUE | 1.5 | 0.14 |
| 2025-01-17 | 17.5 | 9.39 | CALL | 19 | 41 | 73.16 | TRUE | 9.39 | 0 |
| 2025-01-17 | 20 | 7.5 | CALL | 18 | 132 | 71.26 | TRUE | 0.2 | 0.03 |
| 2025-01-17 | 22.5 | 6.6 | CALL | 1 | 57 | 74.69 | TRUE | 6.6 | 0 |
| 2025-01-17 | 25 | 5.36 | CALL | 191 | 2028 | 70.95 | FALSE | 0.26 | 0.05 |
| 2025-01-17 | 30 | 3.81 | CALL | 16 | 675 | 70.42 | FALSE | 0.19 | 0.05 |
| 2025-01-17 | 35 | 2.62 | CALL | 55 | 165 | 68.75 | FALSE | 2.62 | 0 |
| 2025-01-17 | 40 | 2.15 | CALL | 3 | 240 | 69.04 | FALSE | 0.46 | 0.27 |
| 2025-01-17 | 45 | 1.08 | CALL | 0 | 51 | 72.68 | FALSE | 0 | 0 |
| 2025-01-17 | 50 | 1.05 | CALL | 5 | 60 | 69.86 | FALSE | 1.05 | 0 |
| 2025-01-17 | 12.5 | 1.1 | PUT | 0 | 55 | 77.85 | FALSE | 0 | 0 |
| 2025-01-17 | 15 | 1.34 | PUT | 3 | 337 | 72.96 | FALSE | 1.34 | 0 |
| 2025-01-17 | 17.5 | 2.39 | PUT | 0 | 19 | 72.69 | FALSE | 0 | 0 |
| 2025-01-17 | 20 | 3.37 | PUT | 30 | 109 | 73.84 | FALSE | 3.37 | 0 |
| 2025-01-17 | 22.5 | 5.8 | PUT | 0 | 798 | 70.02 | FALSE | 0 | 0 |
| 2025-01-17 | 25 | 6.28 | PUT | 0 | 2343 | 73.74 | TRUE | 0 | 0 |
| 2025-01-17 | 30 | 9.6 | PUT | 0 | 189 | 69.84 | TRUE | 0 | 0 |
| 2025-01-17 | 35 | 12.2 | PUT | 0 | 15 | 72.15 | TRUE | 0 | 0 |
| 2025-01-17 | 40 | 18 | PUT | 0 | 12 | 70.29 | TRUE | 0 | 0 |
| 2025-01-17 | 45 | 0 | PUT | 0 | 0 | 72.39 | TRUE | 0 | 0 |
| 2025-01-17 | 50 | 28.8 | PUT | 0 | 0 | 77.12 | TRUE | 0 | 0 |
Latest NTLA Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 21 | $38.98 |
| Jun 13, 2022 7:59 PM EST | 1 | $39 |
| Jun 13, 2022 7:59 PM EST | 18 | $39 |
| Jun 13, 2022 7:59 PM EST | 33 | $38.91 |
| Jun 13, 2022 7:59 PM EST | 100 | $39 |
Intellia Therapeutics, Inc (NTLA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120040251/0001209191-20-040251-index.htm |
| 2019-03-11 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1652130/000000000019004383/0000000000-19-004383-index.htm |
| 2019-08-29 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1652130/000000000019012968/0000000000-19-012968-index.htm |
| 2019-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000009375119000131/0000093751-19-000131-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000009375120000463/0000093751-20-000463-index.htm |
| 2019-02-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000021545719006721/0000215457-19-006721-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000031506619001135/0000315066-19-001135-index.htm |
| 2019-09-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000031506619001705/0000315066-19-001705-index.htm |
| 2020-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000083423720005186/0000834237-20-005186-index.htm |
| 2018-10-29 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000089924318027590/0000899243-18-027590-index.htm |
| 2018-10-31 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000089924318027815/0000899243-18-027815-index.htm |
| 2018-10-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000089924318027816/0000899243-18-027816-index.htm |
| 2018-11-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000089924318027919/0000899243-18-027919-index.htm |
| 2018-12-20 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000089924318031474/0000899243-18-031474-index.htm |
| 2019-01-24 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000089924319001904/0000899243-19-001904-index.htm |
| 2019-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000089924319001905/0000899243-19-001905-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000089924320006973/0000899243-20-006973-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000089924320006975/0000899243-20-006975-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000089924320006976/0000899243-20-006976-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000089924320006978/0000899243-20-006978-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000089924320006979/0000899243-20-006979-index.htm |
| 2020-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000089924320021784/0000899243-20-021784-index.htm |
| 2019-02-14 | 5 | Annual statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000092542119000049/0000925421-19-000049-index.htm |
| 2019-02-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000093247119005516/0000932471-19-005516-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000095010320002663/0000950103-20-002663-index.htm |
| 2018-06-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000110465918041218/0001104659-18-041218-index.htm |
| 2018-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000110465918045660/0001104659-18-045660-index.htm |
| 2019-02-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000110465919006433/0001104659-19-006433-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000110465920018572/0001104659-20-018572-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000110465920021151/0001104659-20-021151-index.htm |
| 2020-03-30 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1652130/000110465920040260/0001104659-20-040260-index.htm |
| 2020-08-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1652130/000110465920097257/0001104659-20-097257-index.htm |
| 2019-07-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000114036119012576/0001140361-19-012576-index.htm |
| 2019-08-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000114036119014318/0001140361-19-014318-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000114036120002973/0001140361-20-002973-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000114420419007775/0001144204-19-007775-index.htm |
| 2018-05-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312518169541/0001193125-18-169541-index.htm |
| 2018-06-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312518201026/0001193125-18-201026-index.htm |
| 2018-07-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312518222580/0001193125-18-222580-index.htm |
| 2018-08-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312518233902/0001193125-18-233902-index.htm |
| 2018-10-12 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | https://www.sec.gov/Archives/edgar/data/1652130/000119312518298490/0001193125-18-298490-index.htm |
| 2018-10-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312518310737/0001193125-18-310737-index.htm |
| 2018-10-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312518312968/0001193125-18-312968-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312519003270/0001193125-19-003270-index.htm |
| 2019-01-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312519015319/0001193125-19-015319-index.htm |
| 2019-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312519052744/0001193125-19-052744-index.htm |
| 2019-02-27 | POSASR | Post-effective Amendment to an automatic shelf registration statement | https://www.sec.gov/Archives/edgar/data/1652130/000119312519052893/0001193125-19-052893-index.htm |
| 2019-02-27 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1652130/000119312519052968/0001193125-19-052968-index.htm |
| 2019-02-27 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1652130/000119312519052972/0001193125-19-052972-index.htm |
| 2019-04-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312519099432/0001193125-19-099432-index.htm |
| 2019-04-16 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1652130/000119312519107874/0001193125-19-107874-index.htm |
| 2019-05-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312519133878/0001193125-19-133878-index.htm |
| 2019-05-02 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1652130/000119312519135032/0001193125-19-135032-index.htm |
| 2019-05-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312519154097/0001193125-19-154097-index.htm |
| 2019-06-04 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1652130/000119312519165029/0001193125-19-165029-index.htm |
| 2019-08-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312519209778/0001193125-19-209778-index.htm |
| 2019-08-23 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1652130/000119312519228025/0001193125-19-228025-index.htm |
| 2019-08-30 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1652130/000119312519235380/0001193125-19-235380-index.htm |
| 2019-08-30 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1652130/000119312519235386/0001193125-19-235386-index.htm |
| 2019-09-10 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1652130/000119312519241975/0001193125-19-241975-index.htm |
| 2019-09-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312519256137/0001193125-19-256137-index.htm |
| 2019-10-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312519279632/0001193125-19-279632-index.htm |
| 2019-12-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312519314363/0001193125-19-314363-index.htm |
| 2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312520156459/0001193125-20-156459-index.htm |
| 2020-06-01 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1652130/000119312520157348/0001193125-20-157348-index.htm |
| 2020-06-03 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1652130/000119312520159684/0001193125-20-159684-index.htm |
| 2020-06-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312520159705/0001193125-20-159705-index.htm |
| 2020-10-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000119312520263296/0001193125-20-263296-index.htm |
| 2018-05-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919118031692/0001209191-18-031692-index.htm |
| 2018-05-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919118031694/0001209191-18-031694-index.htm |
| 2018-08-10 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919118046243/0001209191-18-046243-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919118063657/0001209191-18-063657-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919118063660/0001209191-18-063660-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919118063663/0001209191-18-063663-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919118063664/0001209191-18-063664-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919119016544/0001209191-19-016544-index.htm |
| 2019-03-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919119018817/0001209191-19-018817-index.htm |
| 2019-05-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919119032076/0001209191-19-032076-index.htm |
| 2019-05-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919119032078/0001209191-19-032078-index.htm |
| 2019-05-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919119032080/0001209191-19-032080-index.htm |
| 2019-05-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919119032081/0001209191-19-032081-index.htm |
| 2019-05-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919119032084/0001209191-19-032084-index.htm |
| 2019-05-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919119032086/0001209191-19-032086-index.htm |
| 2019-05-29 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919119033187/0001209191-19-033187-index.htm |
| 2019-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919119034240/0001209191-19-034240-index.htm |
| 2019-08-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919119044238/0001209191-19-044238-index.htm |
| 2020-05-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120027162/0001209191-20-027162-index.htm |
| 2020-05-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120027165/0001209191-20-027165-index.htm |
| 2020-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120032648/0001209191-20-032648-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120034724/0001209191-20-034724-index.htm |
| 2020-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120037647/0001209191-20-037647-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120037961/0001209191-20-037961-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120037964/0001209191-20-037964-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120037967/0001209191-20-037967-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120037970/0001209191-20-037970-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120037971/0001209191-20-037971-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120037992/0001209191-20-037992-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120040251/0001209191-20-040251-index.htm |
| 2020-07-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120042820/0001209191-20-042820-index.htm |
| 2020-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120047713/0001209191-20-047713-index.htm |
| 2020-09-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120049379/0001209191-20-049379-index.htm |
| 2020-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120050945/0001209191-20-050945-index.htm |
| 2020-10-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120053567/0001209191-20-053567-index.htm |
| 2020-10-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120053583/0001209191-20-053583-index.htm |
| 2020-10-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120054440/0001209191-20-054440-index.htm |
| 2020-10-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120055196/0001209191-20-055196-index.htm |
| 2020-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120057297/0001209191-20-057297-index.htm |
| 2020-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1652130/000120919120057300/0001209191-20-057300-index.htm |
| 2019-07-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000121465919004547/0001214659-19-004547-index.htm |
| 2019-08-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000121465919005075/0001214659-19-005075-index.htm |
| 2018-08-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1652130/000156459018018256/0001564590-18-018256-index.htm |
| 2018-10-31 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1652130/000156459018025733/0001564590-18-025733-index.htm |
| 2018-12-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000156459018030544/0001564590-18-030544-index.htm |
| 2019-02-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1652130/000156459019004680/0001564590-19-004680-index.htm |
| 2019-05-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1652130/000156459019015384/0001564590-19-015384-index.htm |
| 2019-08-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1652130/000156459019028042/0001564590-19-028042-index.htm |
| 2019-10-31 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1652130/000156459019039199/0001564590-19-039199-index.htm |
| 2020-01-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000156459020000550/0001564590-20-000550-index.htm |
| 2020-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000156459020007032/0001564590-20-007032-index.htm |
| 2020-02-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1652130/000156459020007409/0001564590-20-007409-index.htm |
| 2020-02-27 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1652130/000156459020007444/0001564590-20-007444-index.htm |
| 2020-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000156459020010859/0001564590-20-010859-index.htm |
| 2020-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000156459020012963/0001564590-20-012963-index.htm |
| 2020-04-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000156459020016142/0001564590-20-016142-index.htm |
| 2020-04-24 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1652130/000156459020018482/0001564590-20-018482-index.htm |
| 2020-04-24 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1652130/000156459020018497/0001564590-20-018497-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000156459020022377/0001564590-20-022377-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1652130/000156459020022919/0001564590-20-022919-index.htm |
| 2020-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000156459020029961/0001564590-20-029961-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000156459020037260/0001564590-20-037260-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1652130/000156459020037798/0001564590-20-037798-index.htm |
| 2020-10-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000156459020046696/0001564590-20-046696-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1652130/000156459020050887/0001564590-20-050887-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1652130/000156459020050915/0001564590-20-050915-index.htm |
| 2019-01-16 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000165495419000534/0001654954-19-000534-index.htm |
| 2019-03-25 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1652130/000165495419003213/0001654954-19-003213-index.htm |
| 2019-06-06 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1652130/999999999519001290/9999999995-19-001290-index.htm |
| 2019-09-12 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1652130/999999999519002079/9999999995-19-002079-index.htm |
| 2019-03-11 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1652130/999999999719000954/9999999997-19-000954-index.htm |
| 2019-05-09 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1652130/999999999719004137/9999999997-19-004137-index.htm |
| 2020-09-01 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1652130/999999999720004558/9999999997-20-004558-index.htm |
Intellia Therapeutics, Inc (NTLA) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Intellia Therapeutics, Inc (NTLA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1358%Institutional Ownership: 8575%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-06-19 | JEAN FRANCOIS FORMELA | Director | Sell | 1,400.00 | 28.39 | 39,746.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1652130/000110465918041218/0001104659-18-041218-index.htm |
| 2018-07-16 | JEAN FRANCOIS FORMELA | Director | Sell | 1,402.00 | 31.93 | 44,762.36 | 0.00 | https://www.sec.gov/Archives/edgar/data/1652130/000110465918045660/0001104659-18-045660-index.htm |
| 2019-03-01 | Fred E Cohen | Director | Buy | 10,000.00 | 16.89 | 168,936.00 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919119016544/0001209191-19-016544-index.htm |
| 2018-06-19 | JEAN FRANCOIS FORMELA | Director | Sell | 5,286.00 | 27.84 | 147,162.24 | 1,400.00 | https://www.sec.gov/Archives/edgar/data/1652130/000110465918041218/0001104659-18-041218-index.htm |
| 2018-07-16 | JEAN FRANCOIS FORMELA | Director | Sell | 5,284.00 | 30.97 | 163,634.91 | 1,402.00 | https://www.sec.gov/Archives/edgar/data/1652130/000110465918045660/0001104659-18-045660-index.htm |
| 2020-06-16 | Jose E Rivera | EVP, General Counsel | Sell | 5,615.00 | 21.00 | 117,915.00 | 22,282.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120037647/0001209191-20-037647-index.htm |
| 2020-07-15 | Jose E Rivera | EVP, General Counsel | Sell | 5,615.00 | 22.70 | 127,460.50 | 27,524.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120042820/0001209191-20-042820-index.htm |
| 2020-06-16 | Jose E Rivera | EVP, General Counsel | Buy | 10,000.00 | 6.83 | 68,300.00 | 27,897.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120037647/0001209191-20-037647-index.htm |
| 2020-05-26 | Jose E Rivera | EVP, General Counsel | Sell | 5,615.00 | 21.21 | 119,094.15 | 280,107.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120032648/0001209191-20-032648-index.htm |
| 2020-05-26 | Jose E Rivera | EVP, General Counsel | Buy | 10,000.00 | 6.83 | 68,300.00 | 285,722.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120032648/0001209191-20-032648-index.htm |
| 2020-08-18 | Jose E Rivera | EVP, General Counsel | Sell | 5,615.00 | 21.00 | 117,915.00 | 31,909.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120047713/0001209191-20-047713-index.htm |
| 2019-03-06 | ANDREW SCHIERMEIER | EVP, Dev and Corp Strategy | Buy | 3,250.00 | 16.00 | 52,000.00 | 3,250.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919119018817/0001209191-19-018817-index.htm |
| 2020-07-15 | Jose E Rivera | EVP, General Counsel | Buy | 10,000.00 | 6.83 | 68,300.00 | 33,139.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120042820/0001209191-20-042820-index.htm |
| 2020-09-15 | Jose E Rivera | EVP, General Counsel | Sell | 5,615.00 | 21.04 | 118,139.60 | 36,294.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120050945/0001209191-20-050945-index.htm |
| 2020-08-18 | Jose E Rivera | EVP, General Counsel | Buy | 10,000.00 | 6.83 | 68,300.00 | 37,524.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120047713/0001209191-20-047713-index.htm |
| 2020-10-15 | Jose E Rivera | EVP, General Counsel | Sell | 156.00 | 24.55 | 3,829.80 | 40,679.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120055196/0001209191-20-055196-index.htm |
| 2020-10-15 | Jose E Rivera | EVP, General Counsel | Sell | 5,459.00 | 24.19 | 132,053.21 | 40,835.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120055196/0001209191-20-055196-index.htm |
| 2020-09-15 | Jose E Rivera | EVP, General Counsel | Buy | 10,000.00 | 6.83 | 68,300.00 | 41,909.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120050945/0001209191-20-050945-index.htm |
| 2020-11-04 | Jose E Rivera | EVP, General Counsel | Sell | 3,364.00 | 28.00 | 94,192.00 | 42,315.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120057300/0001209191-20-057300-index.htm |
| 2020-11-04 | Jose E Rivera | EVP, General Counsel | Buy | 5,000.00 | 13.88 | 69,400.00 | 45,679.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120057300/0001209191-20-057300-index.htm |
| 2020-10-15 | Jose E Rivera | EVP, General Counsel | Buy | 10,000.00 | 6.83 | 68,300.00 | 46,294.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120055196/0001209191-20-055196-index.htm |
| 2020-10-07 | JOHN M LEONARD | President and CEO | Sell | 5,000.00 | 21.83 | 109,150.00 | 467,352.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120054440/0001209191-20-054440-index.htm |
| 2020-11-04 | JOHN M LEONARD | President and CEO | Sell | 50,000.00 | 26.00 | 1,300,000.00 | 467,352.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120057297/0001209191-20-057297-index.htm |
| 2020-06-03 | JOHN M. LEONARD | President and CEO | Sell | 5,000.00 | 21.83 | 109,150.00 | 467,352.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120034724/0001209191-20-034724-index.htm |
| 2020-07-01 | JOHN M. LEONARD | President and CEO | Sell | 5,000.00 | 21.83 | 109,150.00 | 467,352.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120040251/0001209191-20-040251-index.htm |
| 2020-08-06 | JOHN M. LEONARD | President and CEO | Sell | 5,000.00 | 21.83 | 109,150.00 | 467,352.00 | https://www.sec.gov/Archives/edgar/data/1652130/000089924320021784/0000899243-20-021784-index.htm |
| 2020-09-01 | JOHN M. LEONARD | President and CEO | Sell | 5,000.00 | 21.83 | 109,150.00 | 467,352.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120049379/0001209191-20-049379-index.htm |
| 2020-10-07 | JOHN M LEONARD | President and CEO | Buy | 5,000.00 | 6.83 | 34,150.00 | 472,352.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120054440/0001209191-20-054440-index.htm |
| 2020-06-03 | JOHN M. LEONARD | President and CEO | Buy | 5,000.00 | 6.83 | 34,150.00 | 472,352.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120034724/0001209191-20-034724-index.htm |
| 2020-07-01 | JOHN M. LEONARD | President and CEO | Buy | 5,000.00 | 6.83 | 34,150.00 | 472,352.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120040251/0001209191-20-040251-index.htm |
| 2020-08-06 | JOHN M. LEONARD | President and CEO | Buy | 5,000.00 | 6.83 | 34,150.00 | 472,352.00 | https://www.sec.gov/Archives/edgar/data/1652130/000089924320021784/0000899243-20-021784-index.htm |
| 2020-09-01 | JOHN M. LEONARD | President and CEO | Buy | 5,000.00 | 6.83 | 34,150.00 | 472,352.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120049379/0001209191-20-049379-index.htm |
| 2020-11-04 | JOHN M LEONARD | President and CEO | Buy | 50,000.00 | 6.83 | 341,500.00 | 517,352.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919120057297/0001209191-20-057297-index.htm |
| 2019-03-06 | ANDREW SCHIERMEIER | EVP, Dev and Corp Strategy | Buy | 4,250.00 | 15.50 | 65,875.00 | 7,500.00 | https://www.sec.gov/Archives/edgar/data/1652130/000120919119018817/0001209191-19-018817-index.htm |